Document:

Agreement for Termination of Lease - ARE-San Francisco No. 41, LLC

 Exhibit 10.28 
 AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES 
 This Agreement for
Termination of Lease and Voluntary Surrender of Premises (this “Agreement”) is made as of the 8th day of December, 2008 (the “Execution Date”), by and between ARE-San Francisco No. 41, LLC, a
Delaware limited liability company (“Alexandria”) and Cell Genesys, Inc., a Delaware corporation (“Cell Genesys”) with reference to the following: 
 RECITALS 
 A. Alexandria (as successor-in-interest to
Drawbridge/Forbes, L.L.C., a California limited liability company) and Cell Genesys are parties to that certain Lease dated March 3, 2001, as amended by that certain First Amendment to Lease dated February 20, 2002, and by that certain
Lease Commencement Date Certificate fully executed as of February 24, 2003 (as amended, the “Lease”) for premises located at that certain real property commonly known as 500 Forbes Boulevard, South San Francisco,
California being more particularly described in the Lease (the “Premises”). All initially capitalized terms not defined specifically herein shall have the meanings set forth in the Lease. 
 B. Alexandria is currently negotiating with a third party (“New Tenant”) to enter into a new lease of the Premises (the “New
Lease”). 
 C. Cell Genesys desires to terminate the Lease, which termination will be earlier than the date of termination set forth in the
Lease. 
 D. Alexandria is willing to agree to the early termination of the Lease subject to the terms and conditions set forth in this Agreement.

 NOW, THEREFORE, in consideration of the foregoing, in further consideration of the mutual promises made herein, and for other good and
valuable consideration, receipt of which is acknowledged, Alexandria and Cell Genesys agree as follows: 
 1. Termination Date.
Alexandria and Cell Genesys hereby agree that, except to the extent this Agreement is terminated pursuant to Section 10 hereof, the Lease shall automatically terminate without further action of Alexandria or Cell Genesys on 11:59 p.m. on
January 2, 2009 (“Termination Date”). The Lease shall remain in full force and effect until the Termination Date; provided, that, Cell Genesys shall have no obligation to pay Base Monthly Rent and Additional Rent for the
month of January, 2009; provided, further, if this Agreement is terminated for any reason prior to the Termination Date, then Base Monthly Rent and Additional Rent for the month of January, 2009 shall notwithstanding the foregoing immediately become
due and owing. 
 2. Termination. Subject only to the License, Cell Genesys represents and warrants that it has vacated or will vacate
the Premises on or before the Termination Date. Subject only to the License, Cell Genesys hereby surrenders all rights of possession of the Premises effective as of the Termination Date. Subject only to the License, if Cell Genesys remains in
possession of the Premises after the Termination Date without the express written consent of Alexandria, Cell Genesys shall become a tenant at sufferance upon the terms of the Lease except that the monthly rental shall be equal to 200% of Base
Monthly Rent in effect during December 2008. In addition, subject only to the License, if Cell Genesys remains in possession of the Premises after the date which is 7 days after the Termination Date, then Cell Genesys shall be responsible for all
damages suffered by Alexandria resulting from or occasioned by Cell 

 
Genesys’ holding over, including consequential damages. Subject only to the License, Cell Genesys specifically acknowledges that Cell Genesys’
holdover in the Premises following the Termination Date may, without limitation, result in liability of Alexandria under the New Lease. No holding over by Cell Genesys, whether with or without consent of Alexandria, shall operate to extend the Lease
and this Section 2 shall not be construed as consent for Cell Genesys to retain possession of the Premises following the Termination Date. Acceptance by Alexandria of Base Monthly Rent and Additional Rent after the Termination Date shall
not result in a renewal or reinstatement of the Lease. After the Termination Date, subject only to the License, Cell Genesys shall have no rights of any kind with respect to the Premises. 
 3. Intentionally Deleted. 
 4.
Surrender; Cell Genesys’ FF&E. Notwithstanding anything in the Lease to the contrary, (i) subject only to the License and any other obligations of Cell Genesys with respect to Hazardous Materials which survive the termination of
the Lease, Cell Genesys shall surrender the Premises to Alexandria on the Termination Date broom clean but otherwise in its current as-is condition and Alexandria shall accept the Premises in such condition, (ii) Cell Genesys shall not remove
or restore any Tenant Improvements or Alterations from the Premises, (iii) Cell Genesys shall not remove any desks, cubicles, chairs, credenzas, conference tables or other conference room furniture, reception desks or tables or other reception
area furniture, phone systems, real property fixtures, built-in machinery and equipment, built-in casework and cabinets and other similar additions and improvements built into the Premises so as to become an integral part of the Premises such as
fume hoods which penetrate the roof or plenum area, built-in cold rooms, built-in warm rooms, walk-in cold rooms, walk-in warm rooms, deionized water systems, glass washing equipment, autoclaves, chillers, built-in plumbing, electrical and
mechanical equipment and systems, and any power generator and transfer switchs existing in the Premises as of the Execution Date (collectively, “Cell Genesys’ FF&E”), and (iv) Cell Genesys shall not be required
to perform any restoration of any alterations or installations to the Premises or pay any removal costs thereof. Cell Genesys shall not remove any of Cell Genesys’ FF&E from the Premises without Alexandria’s prior written consent in
Alexandria’s sole and absolute discretion. Cell Genesys has delivered to Alexandria an executed bill of sale in the form attached hereto as Exhibit A (“Bill of Sale”) conveying Cell Genesys’ FF&E to
Alexandria; provided, that the Bill of Sale shall not be effective until the Termination Date. 
 5. Intentionally Deleted.

 6. No Further Obligations. Alexandria and Cell Genesys agree that Alexandria and Cell Genesys are excused as of the Termination
Date from any further obligations with respect to the Lease, excepting only such obligations under the Lease which are, by their terms, intended to survive termination of the Lease, and as otherwise provided herein. In addition, nothing herein shall
be deemed to limit or terminate any common law or statutory rights Alexandria may have with respect to Cell Genesys in connection any Hazardous Materials (as defined in the Lease) or for violations of any governmental requirements or any
requirements of applicable law. 
 7. Removal of Personal Property. Cell Genesys agrees that the Premises shall be surrendered free of
the personal property of Cell Genesys other than Cell Genesys’ FF&E which personal property Cell Genesys shall remove from the Premises on or before the License Expiration Date (as hereinafter defined). Any personal property of Cell Genesys
other than Cell Genesys’ FF&E remaining in the Premises as of the License Expiration Date shall be deemed to be abandoned by Cell Genesys, and may be disposed of by Alexandria, in Alexandria’s sole discretion, without obligation or
liability to Cell Genesys. 
 8. Release of Liability. As of the Termination Date, Cell Genesys releases and 

 
exculpates Alexandria from any liability arising from the Lease, and from the termination of the Lease. As of the License Expiration Date, Cell
Genesys releases and exculpates Alexandria from any liability arising from the License, and from the termination of the License. The foregoing releases extend to all rights of Cell Genesys under Section 1542 of the California Civil Code
and any similar law of any state or territory of the United States, which are hereby expressly waived and relinquished by Cell Genesys. Section 1542 reads: 
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS
OR HER SETTLEMENT WITH THE DEBTOR. 
 _____________________ 
 Cell Genesys’ Initials 
 Cell Genesys acknowledges that this release and waiver are an essential and
material term of this Agreement, without which Alexandria would not become a party to this Agreement. Cell Genesys represents and warrants, that to its knowledge Cell Genesys has no claims against Alexandria arising from the Lease or otherwise with
respect to the Premises. 
 9. Intentionally Deleted. 
 10. Termination Fee. On or before December 8, 2008, Cell Genesys shall pay to Alexandria in immediately available funds, in consideration of Alexandria’s agreement to terminate the Lease, a payment
which shall be in the amount of $14,714,705.50 (the “Termination Fee”). The termination of the Lease shall be subject to the condition precedent that Cell Genesys shall have timely paid the Termination Fee to Alexandria in
immediately available funds. If payment of the Termination Fee is not timely made by Cell Genesys, then Alexandria may in its sole and absolute discretion deliver written notice to Cell Genesys terminating this Agreement, in which case, this
Agreement shall be null and void and shall thereafter be of no further force of effect. Alexandria and Cell Genesys acknowledge and agree that Alexandria’s agreement to terminate the Lease pursuant to the terms and conditions set forth in this
Agreement will result in immediate and direct benefits to Cell Genesys and the Termination Fee is being paid by Cell Genesys in consideration of such benefits. Alexandria acknowledges that the Termination Fee includes all Base Monthly Rent and
Additional Rent payable by Cell Genesys under the Lease up to and including the Termination Date. 
 11. Memorandum of Lease.
Alexandria and Cell Genesys acknowledge and agree that a memorandum of the Lease was recorded March 7, 2002 as Instrument No. 2002-042198 in the Official Records of San Mateo County, California (“Memorandum of
Lease”). Cell Genesys has delivered to Alexandria a quitclaim deed terminating the Memorandum of Lease in the form of Exhibit B attached hereto executed by Cell Genesys and acknowledged by a notary (the “Quitclaim
Deed”); provided, that, the Quitclaim Deed shall not be effective and Alexandria shall not cause the Quitclaim Deed to be recorded until the Termination Date. 
 12. Letter of Credit. Alexandria and Cell Genesys acknowledge and agree that Alexandria is holding a security deposit in the form of a standby
letter of credit in the amount of $1,899,357.00 securing Cell Genesys’ obligations under the Lease (the “Letter of Credit”). Notwithstanding anything in the Lease to the contrary, Alexandria shall return the original
Letter of Credit along with a letter on Alexandria’s letterhead instructing the issuing bank to cancel the Letter of Credit to Cell Genesys on or before March 16, 2009. In addition to the other purposes set forth in the Lease, Alexandria
may apply the Security Deposit to remedy any default or other 

 
failure by Cell Genesys in fully performing Cell Genesys’ obligations under this Agreement, including, without limitation, the disgorgement of the
Termination Fee by Alexandria or any requirement to repay the Termination Fee to Cell Genesys, including, without limitation, as a result of a preference action in bankruptcy. 
 13. No Assignment or Subletting. Cell Genesys represents and warrants that Cell Genesys has not assigned, subleased, mortgaged, pledged,
encumbered or otherwise transferred any interest in the Lease or Cell Genesys’ FF&E and that Cell Genesys holds the interest in the Premises set forth in the Lease as of the date of this Agreement. Notwithstanding anything to the contrary
set forth in the Lease, Cell Genesys shall not assign, sublease, mortgage, pledge, encumber or otherwise transfer any interest in the Lease or Cell Genesys’ FF&E, including, without limitation, any assignment or subletting to a Permitted
Assignee. 
 14. No Further Modification/Counterparts/Authorization. This Agreement may not be modified or terminated except in
writing signed by all parties. This Agreement may be executed in counterparts which, taken together, will constitute one agreement binding on the parties. The persons signing below represent and warrant that they are duly authorized to execute this
Agreement. 
 15. Successors and Assigns. The covenants and agreements herein contained shall inure to the benefit and be binding upon
the parties and their respective successors and assigns. 
 16. Attorneys’ Fees. In the event of a dispute between the parties,
the prevailing party shall be entitled to have its reasonable attorneys’ fees and costs paid by the other party. 
 17. Conflict of
Laws. This Agreement shall be governed by the laws of the state in which the Premises are located. 
 18. Headings. Section
headings in this Agreement are for convenience of reference only, and shall not be construed to affect or modify the substantive meaning of any Section hereof. 
 19. Cell Genesys’ Acknowledgment. Cell Genesys acknowledges that it has read the foregoing provisions, understands them, and is bound by them. Time is of the essence in this Agreement. 
 20. License. 
 (a) License.
Notwithstanding the termination of the Lease, Alexandria hereby gives Cell Genesys an exclusive, irrevocable license (i) to use the Buildings for general office purposes solely related to Cell Genesys’ business and for no other purposes,
(ii) subject to Alexandria’s rules and regulations, for ingress and egress to and from the Buildings, (iii) subject to Alexandria’s rules and regulations, for ingress and egress to and from the Buildings for the purposes of
removing Cell Genesys’ personal property other than Cell Genesys’ FF&E from the Buildings, (iv) subject to Alexandria’s rules and regulations, to park in those areas designated for non-reserved parking, in common with other
occupants of the Buildings and (v) to use Cell Genesys’ FF&E (collectively, the “License”). The License shall automatically expire on 11:59 p.m. on January 30, 2009 (“Outside License Expiration
Date”); provided, that, Cell Genesys may elect to terminate the License prior to the Outside License Expiration Date by providing 5 days prior written notice to Alexandria (a “License Termination Notice”). The
date which is the earlier of (i) the Outside License Expiration Date and (ii) the date upon which Cell Genesys (A) has given Alexandria a License Termination Notice and (B) has fully vacated the Buildings in the condition
required by this Section 20 and removed all of Cell Genesys’ personal property except 

 
Cell Genesys’ FF&E from the Buildings shall be referred to herein as, the “License Expiration Date”. If the Lease terminates
for any reason other than pursuant to this Agreement, then the License shall be null and void and of no further force and effect. 
 (b)
Terms and Conditions. Except to the extent expressly in conflict with the preceding paragraph (a) (in which case the preceding paragraph (a) shall control), the License shall be subject to the terms and conditions of
the Lease; provided, that, Cell Genesys shall have no obligation to pay Base Monthly Rent, Additional Rent or utility costs following the Termination Date and Cell Genesys shall be a licensee of the Buildings and not a tenant. Upon the License
Expiration Date, if requested by Alexandria, Cell Genesys shall promptly execute and deliver to Alexandria a written agreement in a form satisfactory to Alexandria evidencing the termination of the License and Cell Genesys’ right to possession
of the Buildings. 
 (c) Holding Over. If Cell Genesys remains in possession of the Buildings after the Outside License Expiration
Date without the express written consent of Alexandria, Cell Genesys shall become a non-exclusive licensee upon the terms of the License, which License shall be revocable thereafter, except that Cell Genesys shall owe Alexandria a fee equal to 200%
of Base Monthly Rent in effect during December 2008 prorated on a daily basis (“License Fee”) for each day after the Outside License Expiration Date that Cell Genesys continues to remain in possession of the Buildings. In
addition, if Cell Genesys remains in possession of the Buildings after the date which is 7 days after the Outside License Expiration Date, then Cell Genesys shall be responsible for all damages suffered by Alexandria resulting from or occasioned by
Cell Genesys’ holding over, including consequential damages and (C) Alexandria may pursue all rights and remedies available at law or in equity against Cell Genesys as a holdover licensee of any portion of the Buildings which Cell Genesys
continues to occupy. Cell Genesys specifically acknowledges that Cell Genesys’ holdover in the Buildings following the Outside License Expiration Date may, without limitation, result in liability of Alexandria under the New Lease. No holding
over by Cell Genesys with respect to the Buildings, whether with or without consent of Alexandria, shall operate to extend the Lease or the License and this Section 20 shall not be construed as consent for Cell Genesys to retain
possession of the Buildings following the Outside License Expiration Date. Acceptance by Alexandria of the License Fee after the Outside License Expiration Date shall not result in a renewal or reinstatement of the Lease or the License. After the
Outside License Expiration Date, Cell Genesys shall have no rights of any kind with respect to the Buildings, the License or otherwise. 
 (d) Surrender. Cell Genesys shall surrender the Buildings to Alexandria on or before the Outside License Expiration Date in the same condition required under Section 4 above as to the Premises. 
 (e) Cooperation. Cell Genesys acknowledges and agrees that following the execution and delivery of the New Lease, Alexandria, New Tenant and their
architects, engineers, design development staff, consultants and agents may immediately begin certain design and development work related to New Tenant’s use and occupancy thereof (“Preparation Work”); provided, that,
the Preparation Work shall not include the construction of any improvements within the Buildings prior to the License Expiration Date, and shall not unreasonably interfere with Cell Genesys’ operations at the Buildings. Subject to the
foregoing, during Cell Genesys’ use of the License and occupancy of the Buildings, Cell Genesys shall fully cooperate with Alexandria and New Tenant regarding the performance of the Preparation Work. 
 21. Severability. If any clause or provision of this Agreement (including the License) is illegal, invalid or unenforceable under present or
future laws, then and in that event, it is the intent of the parties hereto that the remainder of this Agreement, and the validity, enforceability and legality thereof, shall not be affected or impaired thereby in any way. 

 22. Incorporation by Reference. All exhibits and addenda attached hereto are hereby incorporated
into this Agreement and made a part hereof. 
 23. Brokers. Cell Genesys and Alexandria each represents and warrants that no broker,
agent or other person (collectively, “Broker”) is owed any commission or other form of compensation in connection with the execution and delivery of this Agreement. Cell Genesys and Alexandria each hereby agree to indemnify
and hold the other harmless from and against any claims by any Broker claiming a commission or other form of compensation by virtue of having dealt with Cell Genesys or Alexandria, as applicable, with regard to this Agreement. 
 24. Confidentiality Provisions. 
 (a)
Confidential Information. Except as expressly permitted in this Section 24, neither party nor its agents, servants, employees, invitees and contractors will, without the prior written consent of the other party, disclose any
Confidential Information of the other party to any third party. Information will be considered “Confidential Information” of a party if either (a) it is disclosed by the party to the other party in tangible form and is conspicuously
marked “Confidential”, “Proprietary” or the like; or (b) it is disclosed by one party to the other party in non-tangible form and is identified as confidential at the time of disclosure. In addition, notwithstanding anything
in this Agreement to the contrary, the terms of this Agreement (but not its mere existence) will be deemed Confidential Information of each party. 
 (b) Confidential Information—Exceptions. Other than the terms and conditions of this Agreement, information will not be deemed Confidential Information hereunder if such information (a) is known to the receiving party prior
to receipt from the disclosing party directly or indirectly from a source other than one having an obligation of confidentiality to the disclosing party; (b) becomes known (independently of disclosure by the disclosing party) to the receiving
party directly or indirectly from a source other than one having an obligation of confidentiality to the disclosing party; (c) becomes publicly known or otherwise ceases to be secret or confidential, except through a breach of this Agreement by
the receiving party; or (d) is independently developed by the receiving party. The terms and conditions of this Agreement will cease being confidential if, and only to the extent that, they become publicly known, except through a breach of this
Agreement by the receiving party. 
 (c) Confidentiality—Exceptions. Each party will secure and protect the Confidential
Information of the other party (including, without limitation, the terms of this Agreement) in a manner consistent with the steps taken to protect its own trade secrets and confidential information, but not less than a reasonable degree of care.
Each party may disclose the other party’s Confidential Information where (a) the disclosure is required by applicable law or regulation or by an order of a court or other governmental body having jurisdiction after giving reasonable notice
to the other party with adequate time for such other party to seek a protective order; (b) if in the opinion of counsel for such party, disclosure is advisable under any applicable securities laws regarding public disclosure of business
information; (c) the disclosure is reasonably necessary and is to that party’s or its affiliates’ employees, officers, directors, attorneys, accountants, consultants and other advisors, or the disclosure is otherwise necessary for a
party to exercise its rights and perform its obligations under this Agreement, so long as in all cases the disclosure is no broader than necessary and the party who receives the disclosure agrees prior to receiving the disclosure to keep the
information confidential or (d) the disclosure is reasonably necessary for a party to conclude a business transaction. Each party is responsible for ensuring that any Confidential Information of the other party that the first party discloses
pursuant to this Section 24 is kept confidential by the person receiving the disclosure. 
 25. OFAC. Cell Genesys
is currently (a) in compliance with and shall at all times prior to the expiration of the License remain in compliance with the regulations of the Office of 

 
Foreign Assets Control (“OFAC”) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto
(collectively, the “OFAC Rules”), (b) not listed on, and shall not during the term of this Lease be listed on, the Specially Designated Nationals and Blocked Persons List maintained by OFAC and/or on any other similar
list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.

 26. Notices. All notices or other communications between the parties shall be in writing and shall be deemed duly given upon
delivery or refusal to accept delivery by the addressee thereof if delivered in person, or upon actual receipt if delivered by reputable overnight guaranty courier, addressed and sent to the parties at the following addresses: 
 If to Alexandria: 
 ARE-San Francisco
No. 41, LLC 
 c/o Alexandria Real Estate Equities, Inc. 
 385 E. Colorado Boulevard, Suite 299 
 Pasadena, CA 91101 
 Attention: Corporate Secretary 
 with a copy
to: 
 Paul, Hastings, Janofsky & Walker LLP 
 55 Second Street, 24th Floor 
 San Francisco, CA 94105 
 Attention: Stephen I. Berkman, Esq. 
 If to
Cell Genesys: 
 Cell Genesys 
 500 Forbes Boulevard 
 South San Francisco, CA 94080 
 Attention: Sharon E. Tetlow 
 with a copy to: 
 Holme Roberts & Owen LLP 
 560
Mission Street 25th Floor 
 San Francisco, CA 94105 
 Attention: Kenneth R. Whiting. Esq. 
 Alexandria and Cell Genesys may from time to time by written notice to the other
designate another address for receipt of future notices. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 ALEXANDRIA: 
  

							
	 ARE-SAN FRANCISCO NO. 41, LLC,
 a Delaware
limited liability company

		
	By:	 	 ALEXANDRIA REAL ESTATE EQUITIES, L.P.,
 a
Delaware limited partnership, managing member

			
		 	By:	 	 ARE-QRS CORP.,
 a Maryland corporation,
general partner

		 		 	By:	 	/S/    ERIC S. JOHNSON
		 		 	Name:	 	Eric S. Johnson
		 		 	Title:	 	 Assistant Vice President
 Real Estate Legal Affairs

	
	 CELL GENESYS:
  
 CELL GENESYS, INC.,
 a Delaware corporation

		
	By:	 	/S/    STEPHEN A. SHERWIN, M.D.
	Name:	 	Stephen A. Sherwin, M.D.
	Title:	 	Chairman and CEO

 EXHIBIT A 
 FORM BILL OF SALE 
 THIS BILL OF SALE (“Bill of Sale”) is made as of
December     , 2008, by CELL GENESYS, INC., a Delaware corporation (“Cell Genesys”), to ARE-SAN FRANCISCO NO. 41, LLC, a Delaware limited liability company
(“Alexandria”) 
 RECITALS 
 A. Alexandria (as successor-in-interest to Drawbridge/Forbes, L.L.C., a California limited liability company) and Cell Genesys are parties to that
certain Lease dated March 3, 2001, as amended by that certain First Amendment to Lease dated February 20, 2002, as amended by that certain Lease Commencement Date Certificate fully executed as of February 24, 2003 (as amended, the
“Lease”) for premises located at that certain real property commonly known as 500 Forbes Boulevard, South San Francisco, California being more particularly described in the Lease. 
 B. Alexandria and Cell Genesys have entered into that certain Agreement for Termination of Lease and Voluntary Surrender of Premises dated as of
December     , 2008 (the “Termination Agreement”), with respect to, among other things, the termination of the Lease and the conveyance of “Cell Genesys’ FF&E” (as
defined in the Termination Agreement) effective on January 2, 2009 to Alexandria. 
 C. The Termination Agreement requires Cell
Genesys to convey all of Cell Genesys’ right, title and interest in and to Cell Genesys’ FF&E to Alexandria. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Cell Genesys hereby agrees as follows: 
  

	1.	Unless the context otherwise requires, all capitalized terms used but not otherwise defined herein shall have the respective meanings provided therefor in the Termination Agreement.

  

	2.	As of the Termination Date, Cell Genesys does hereby unconditionally, absolutely, and irrevocably grant, bargain, sell, transfer, assign convey, set over and deliver unto Alexandria
all of Cell Genesys’ right, title and interest in and to Cell Genesys’ FF&E. This Bill of Sale shall not be effective until the Termination Date. 

  

	3.	Cell Genesys represents and warrants that its title to Cell Genesys’ FF&E is free and clear of all liens, mortgages, pledges, security interests, prior assignments,
encumbrances and claims of any nature. Cell Genesys hereby expressly disclaims any other warranty, express or implied whatsoever with respect to Cell Genesys’ FF&E. 

  

	4.	This Bill of Sale shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and assigns.

  

	5.	This Bill of Sale and the legal relations of the parties hereto shall be governed by and construed and enforced in accordance with the laws of the State of California, without
regard to its principles of conflicts of law. 

 [ Signature on next page ] 

 IN WITNESS WHEREOF, this Bill of Sale was made and executed as of the date first above written.

  

			
	 CELL GENESYS:
  
 CELL GENESYS, INC.,
 a Delaware corporation

		
	By:	 	 
	Name:	 	 
	Title:	 	 

 EXHIBIT B 
 FORM QUITCLAIM DEED 
  

			
	 RECORDING REQUESTED BY
 AND WHEN RECORDED MAIL TO:
  
 ARE-San Francisco No. 41, LLC
 c/o Alexandria Real Estate Equities, Inc.
 385 East Colorado Blvd., Suite 299

 Pasadena, CA 91101
 Attention: Corporate Secretary

 
	 	 

 (Space Above Line for Recorder’s Use Only) 
 APN: 015-210-140 
 DOCUMENTARY TRANSFER TAX: $0.00 
 QUITCLAIM DEED 
 DRAWBRIDGE/FORBES,
LLC, a California limited liability company (“Drawbridge/Forbes”) and CELL GENESYS, INC., a Delaware corporation (“Grantor”) entered into that certain Lease dated March 31, 2001 (as amended to date, the “Lease”)
affecting that certain real property located in the City of South San Francisco, County of San Mateo, State of California commonly known as 500 Forbes Boulevard being more particularly described on Exhibit A attached hereto and incorporated
herein by reference (the “Property”). 
 Drawbridge/Forbes and Grantor recorded that certain Memorandum of Lease on March 7,
2002 as Instrument No. 2002-042196 in Official Records of San Mateo County (the “Memorandum”) memorializing the existence of the Lease. 
 ARE-SAN FRANCISCO NO. 41, LLC, a Delaware limited liability company (“Grantee”) has succeeded to Drawbridge/Forbes’ interest in the Property and the Lease. 
 Grantor and Grantee have terminated the Lease effective on January 2, 2009 and desire this Quitclaim Deed to be executed and recorded in order to
terminate the Memorandum and to evidence the termination of the Lease and Grantee’s surrender of all rights of possession of the Property. 
 FOR A VALUABLE CONSIDERATION, receipt of which is hereby acknowledged, Grantor hereby does remise, release and forever quitclaim to Grantee the Property. 
 [SIGNATURE ON NEXT PAGE] 
 Dated: December     , 2008 

			
	 CELL GENESYS, INC.,
 a Delaware corporation

		
	By:	 	 
	Name:	 	 
	Title:	 	 

 State of California 
  

					
	County of	  	  
	  	

									
					
	On	  	                              
	  	before me,	  		  	
			
	  
	  	,	  	
		  	Date	  		  	Here Insert Name and Title of Officer personally appeared
	
	  

	Name(s) of Signer(s)

			
		
	  
	  	,

  

					
	 who proved to me on the basis of satisfactory evidence to be the person(s) whose
name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf
of which the person(s) acted, executed the instrument.
  
 I certify under PENALTY OF
PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.
  
 WITNESS my hand and official seal.
	  	Place Notary Seal Above
			
	Signature	  	  
	  	
		  	Signature of Notary Public	  	

 EXHIBIT A TO FORM QUITCLAIM DEED 
 LEGAL DESCRIPTION 
 THE LAND REFERRED TO HEREIN BELOW IS
SITUATED IN THE CITY OF SOUTH SAN FRANCISCO, COUNTY OF SAN MATEO, STATE OF CALIFORNIA, AND IS DESCRIBED AS FOLLOWS: 
 PARCEL 12, AS SHOW UPON THE PARCEL MAP
ENTITLED, “PARCEL MAP BEING A RESUBDIVISION OF A PORTION OF LOT 5, BLOCK 4, CABOT, CABOT & FORBES INDUSTRIAL PARK, UNIT NO. 1, RECORDED FEBRUARY 26, 1965, IN VOLUME 61 OF MAPS, AT PAGES 45 THROUGH 49, AND A PORTION OF THE LANDS OF
CABOT, CABOT & FORBES CALIFORNIA PROPERTIES, INC. (BOOK 4663 OF OFFICIAL RECORDS, AT PAGE 546), ALSO BEING A RESUBDIVISION OF LOT 10 AS SHOWN ON THAT PARCEL MAP RECORDED JUNE 17, 1969, IN BOOK 8 OF PARCEL MAPS, AT PAGE 5, FILED IN
THE OFFICE OF THE RECORDER OF THE COUNTY OF SAN MATEO, STATE OF CALIFORNIA, ON AUGUST 15, 1969, IN BOOK 8 OF PARCEL MAPS, AT PAGE 23, EXCEPTING THEREFROM WATER RIGHTS AS LIE BENEATH THE SURFACE OF THE EARTH, AS DESCRIBED IN QUITCLAIM DEED
FROM CABOT, CABOT & FORBES CALIFORNIA PROPERTIES, INC., A DELAWARE CORPORATION, TO CALIFORNIA WATER SERVICE COMPANY, A CALIFORNIA CORPORATION, RECORDED MARCH 23, 1965, IN BOOK 4917, PAGE 314, SERIES NO. 29235-Y, SAN MATEO COUNTY
RECORDS. 
 APN: 015-210-140Agreement for Termination of Lease - BMR-Bridgeview Technology Park II, LLC

 Exhibit 10.29 
 AGREEMENT FOR TERMINATION OF LEASE AND 
 VOLUNTARY SURRENDER OF PREMISES 
 This Agreement for Termination of Lease and Voluntary Surrender of Premises (this “Agreement”) is made as of the 6th day of
March, 2009 (the “Execution Date”), by and between BMR-Bridgeview Technology Park II LLC, a Delaware limited liability company (“BMR”), and Cell Genesys, Inc., a Delaware corporation (“Cell
Genesys”), with reference to the following: 
 RECITALS 
 A. BMR (as successor-in-interest to F&S Hayward II, LLC, a Delaware limited liability company) and Cell Genesys are parties to that certain Lease
Agreement dated as of January 7, 2002 (as the same may have been amended, supplemented or otherwise modified from time to time, the “Lease”) for premises (the “Premises”) located at that certain
real property commonly known as 24590 Clawiter Road, Hayward, California, being more particularly described in the Lease. 
 B. Cell Genesys
desires to terminate the Lease earlier than the expiration date set forth in the Lease, and BMR is willing to agree to the early termination of the Lease as set forth in this Agreement. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing, in further
consideration of the mutual promises made herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, BMR and Cell Genesys agree as follows: 
 1. Termination Date. BMR and Cell Genesys hereby agree that, subject only to fulfillment or waiver of the Termination Conditions (as hereinafter
defined), the Lease shall terminate automatically (except for the Surviving Obligations, as hereinafter defined) without further action of BMR or Cell Genesys at 11:59 p.m. PST on March 6th, 2009 (the “Termination
Date”); provided, however, BMR shall look solely to the Termination Fee for any amounts of Rent coming due in March 2009. If the Termination Conditions have not been fulfilled or waived by March 31, 2009, then, upon written notice
by BMR or Cell Genesys to the other party, this Agreement shall be null and void and of no further force or effect. If neither party elects to void this Agreement pursuant to the preceding sentence by 11:59 p.m. PST on April 7, 2009, such right
to void this Agreement shall be waived and this Agreement shall remain in full force and effect. 
 2. Termination. On the Termination
Date, the Lease shall terminate, except for the Surviving Obligations. From and after the Termination Date, Cell Genesys will cease occupying the Premises pursuant to the Lease. 

 3. Surrender; FF&E. Notwithstanding anything in the Surrender Obligations (as hereinafter
defined) to the contrary, (a) Cell Genesys shall surrender the Premises and all alterations and improvements therein to BMR on the Termination Date in their current “as is” condition with all Premises systems and equipment therein in
good working order (to the extent the responsibility of Cell Genesys under the Lease) and BMR shall accept the Premises and such alterations and improvements in such condition, (b) Cell Genesys shall not remove any Tenant improvements or
alterations from the Premises, (c) Cell Genesys shall not remove any fixed asset listed on Exhibit A hereto (the “Fixed Asset List”) nor remove any other similar additions and improvements built in and existing in
the Premises as of the Execution Date, as such fixed assets have become an integral part of the real property referred to as the “Premises”, (d) Cell Genesys shall deliver to BMR those items set forth on the Building Turnover List
attached as Exhibit B hereto (“Building Turnover List”), and BMR shall be entitled to use and disclose to third parties any marketing materials prepared by, or on behalf of Cell Genesys in connection with the Premises,
but without any warranty or representation by Cell Genesys (the items listed on the Fixed Asset List and Building Turnover List being referred to herein collectively as the “FF&E”), and (e) Cell Genesys shall not be
required to perform any restoration or any alterations or installations to the Premises or pay any removal costs thereof. The obligations of Cell Genesys under Sections 12.2 and 29 of the Lease, are hereinafter sometimes referred to as the
“Surrender Obligations”. The parties acknowledge that the FF&E shall become the property of BMR effective upon the Termination Date, subject only to fulfillment or waiver of the Termination Conditions, and that Cell
Genesis shall keep in effect any insurance required by the Lease until the fulfillment or waiver of the Termination Conditions. Cell Genesys does hereby grant, bargain, sell, transfer, assign, convey, set over and deliver unto BMR as of the
Termination Date all of Cell Genesys’ right, title and interest in and to the FF&E subject only to fulfillment or waiver of the Termination Conditions. 
 4. Stock Purchase Agreement. Upon the satisfaction of the Termination Condition listed in Section 8(d) below (BMR’s lender shall have consented to the termination of the lease between BMR and Cell
Genesys with respect to the Premises located at 24570 Clawiter Road, Hayward, California,), Cell Genesys and BioMed Realty, L.P. shall immediately execute, deliver and commence performance of the Stock Purchase Agreement in the form attached as
Exhibit C (the “Stock Purchase Agreement”) providing for the issuance of 1,000,000 shares (the “Shares”) of common stock to BioMed Realty, L.P. 
 5. No Further Obligations. BMR and Cell Genesys agree that BMR and Cell Genesys are excused as of the Termination Date from any further
obligations with respect to the Lease, excepting only the obligations herein, the Surrender Obligations and the indemnity obligations of Cell Genesys under Sections 15.1 and 29.5 of the Lease (collectively with the Surrender Obligations, the
“Surviving Obligations”). In addition, nothing herein shall be deemed to limit or terminate any common law or statutory rights BMR may have with respect to Cell Genesys in connection with the Surviving Obligations.

 6. Removal of Movable Personal Property. Cell Genesys agrees that the Premises shall be surrendered free of the movable personal
property of Cell Genesys other than the FF&E, which movable personal property Cell Genesys shall remove from the Premises on or before the Termination Date. Any movable personal property of Cell Genesys other than the FF&E remaining in the
Premises as of the Termination Date shall be deemed to be abandoned by Cell Genesys and may be disposed of by BMR, in BMR’s sole discretion, without obligation or liability to Cell Genesys. 
  

 2 

 7. Release of Liability. As of the Termination Date, except as set forth herein and except for the
Surviving Obligations, each of BMR and Cell Genesys releases and exculpates the other from any claim, action, cause of action, obligation, cost, demand and liability of every type and nature, known and unknown, arising from or connected with the
Lease or from the termination of the Lease. The foregoing releases extend to all rights of BMR and Cell Genesys under Section 1542 of the California Civil Code and any similar law of any state or territory of the United States, which are hereby
expressly waived and relinquished by BMR and Cell Genesys. Section 1542 reads: 
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE
CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR. 
  

					
			
	 	 		 	 
	Cell Genesys’ Initials	 		 	BMR’s Initials

 8. Termination Conditions. The termination of the Lease shall be subject to the fulfillment
or waiver of the following conditions for the benefit of BMR (collectively, the “Termination Conditions”): (a) Cell Genesys shall have paid the Termination Fee (as defined below) within two business days after written
notification from BMR that it has received the lender consent described in clause (d) below, (b) Cell Genesys shall have delivered, or caused to have been delivered, to BMR a share certificate in BMR’s name representing the Shares
within two business days after the mutual execution of the Stock Purchase Agreement, (c) Cell Genesys shall have delivered to BMR the FF&E and (d) BMR’s lender shall have consented to the termination of the lease between BMR and
Cell Genesys with respect to the Premises located at 24570 Clawiter Road, Hayward, California. 
 9. Termination Fee. Cell Genesys
shall pay to BMR in immediately available funds, in consideration of BMR’s agreement to terminate the Lease, a payment in the amount of Three Million Three Hundred Ten Thousand Five Hundred Thirty-Six Dollars ($3,310,536) (the
“Termination Fee”). BMR acknowledges that all Base Rent and Additional Rent payable by Cell Genesys under the Lease up to and including February 28, 2009 have been paid. 
 10. Return of Letter of Credit. BMR and Cell Genesys acknowledge and agree that BMR is holding a security deposit in the form of a standby letter
of credit in the amount of $990,000 (the “Letter of Credit”). Notwithstanding anything in the Lease to the contrary, provided that the Lease is terminated in accordance with this Agreement, within 10 business days following
the occurrence of the last of the Termination Conditions, BMR shall deliver to Cell Genesys the original Letter of Credit along with a letter on BMR’s letterhead instructing the issuing bank to cancel the Letter of Credit. 
  

 3 

 11. No Assignment, Subletting or Encumbrances. Cell Genesys represents and warrants that it has
not assigned, subleased, mortgaged, pledged, encumbered or otherwise transferred any interest in the Lease or the FF&E and that Cell Genesys holds the entire lessees’ interests in the Premises conveyed by the Lease as of the Execution Date.
Notwithstanding anything to the contrary set forth in the Lease, Cell Genesys shall not assign, sublease, mortgage, pledge, encumber or otherwise transfer any interest in the Lease or the FF&E prior to the Termination Date. Cell Genesys further
represents and warrants that its title to the FF&E is free and clear of all liens, mortgages, pledges, security interests, prior assignments (other than those that have been disclosed to BMR in writing), encumbrances and claims of any nature,
and agrees to indemnify BMR for all losses, costs and expenses (including reasonable attorneys’ fees) incurred by BMR as a result of a breach of such representation and warranty. Cell Genesys hereby assigns and transfers to BMR any third-party
warranty to or guaranty of the FF&E to the extent transferrable and hereby expressly disclaims any other warranty, express or implied, whatsoever with respect to the FF&E. 
 12. No Further Modification/Counterparts/Authorization/Waiver. This Agreement may not be modified or terminated except in writing signed by all
parties. This Agreement may be executed in counterparts which, taken together, will constitute one agreement binding on the parties. The persons signing below represent and warrant that they are duly authorized to execute this Agreement. No covenant
or condition of this Agreement in favor of any party shall be deemed waived unless expressly waived in writing by an officer of such party. 
 13. Successors and Assigns. The covenants and agreements herein contained shall inure to the benefit and be binding upon the parties and their respective successors and assigns, whether by merger, sale, consolidation or otherwise.

 14. Attorneys’ Fees. In the event of a dispute between the parties, the prevailing party shall be entitled to have its
reasonable attorneys’ fees and costs paid by the other party. 
 15. Conflict of Laws. This Agreement shall be governed by the
laws of the state in which the Premises are located. 
 16. Headings. Section headings in this Agreement are for convenience of
reference only, and shall not be construed to affect or modify the substantive meaning of any Section hereof. 
 17. Severability. If
any clause or provision of this Agreement is illegal, invalid or unenforceable under present or future laws, then and in that event, it is the intent of the parties hereto that the remainder of this Agreement, and the validity, enforceability and
legality thereof, shall not be affected or impaired thereby in any way. 
 18. Incorporation by Reference. All exhibits and addenda
attached hereto are hereby incorporated into this Agreement and made a part hereof. 
 19. Brokers. Cell Genesys and BMR each
represents and warrants that no broker, agent or other person (collectively, “Broker”) is owed any commission or other form of compensation in connection with the execution and delivery of this Agreement. Cell Genesys and BMR
each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker claiming a commission or other form of compensation by virtue of having dealt with Cell Genesys or BMR, as applicable, with regard to this
Agreement. 
  

 4 

 20. Notices. All notices or other communications between the parties shall be in writing and shall
be deemed duly given upon delivery or refusal to accept delivery by the addressee thereof if delivered in person, or upon actual receipt if delivered by reputable overnight guaranty courier, addressed and sent to the parties at the following
addresses: 
 If to BMR: 
 BMR-Bridgeview Technology Park II LLC 
 17190 Bernardo Center Drive 
 San Diego, CA 92128 
 Attn: Vice President,
Development 
 with a copy to: 
 BMR-Bridgeview Technology Park II LLC 
 17190 Bernardo Center Drive 
 San Diego, CA 92128 
 Attn: Vice President,
Real Estate Counsel 
 If to Cell Genesys: 
 400 Oyster Point Boulevard, Suite 525 
 South San Francisco, CA 94080 
 Attn: Sharon Tetlow 
 with a copy to:

 Holme Roberts & Owen LLP 
 560 Mission Street 25th Floor 
 San Francisco, CA 94105 
 Attn: Kenneth R. Whiting. Esq. 
 BMR and Cell Genesys may
from time to time by written notice to the other designate another address for receipt of future notices. 
 21. Consultant Consent.
BMR, or an affiliate of BMR, may engage as consultants certain employees or former employees designated by Cell Genesys (the “Designated Personnel”) to assist in the assessment of the suitability of the Premises for various future
uses and tenants (the “Suitability Assessment”). Cell Genesys hereby (a) consents to the participation of such Designated Personnel in the Suitability Assessment to the extent that such participation is limited to providing
Suitability Information (as defined below) and (b) waives any duty of confidentiality of the Designated Personnel to Cell Genesys with regard to Suitability Information that may be provided by the Designated Personnel in connection with the
Suitability Assessment. For the purposes of this Section 21, “Suitability Information” shall mean information related to the physical characteristics of the manufacturing plant and equipment, the 

  

 5 

 
general operational aspects of the manufacturing plant and equipment, and the general capacity and utility flows associated with the manufacturing plant and
equipment, but expressly excluding any information related to Cell Genesys personnel matters, financial matters (except financial matters relating to the lease or purchase of the FF&E), clinical data, proprietary processes, intellectual property
(including, without limitation, trade secrets) and any other information not reasonably related to the physical characteristics of the manufacturing plant and equipment and general operational aspects of the activities previously employed at the
Premises by Cell Genesys. 
 [Remainder of page intentionally left blank.] 
  

 6 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	BMR:
	
	 BMR-BRIDGEVIEW TECHNOLOGY PARK II LLC,
 a
Delaware limited liability company

		
	By:	 	/S/ KENT GRIFFIN
	Name:	 	Kent Griffin
	Its:	 	President

  

			
	CELL GENESYS:
	
	 CELL GENESYS, INC.,
 a Delaware corporation

		
	By:	 	/S/ SHARON TETLOW
	Name:	 	Sharon Tetlow
	Its:	 	CFO

  

 7 

 EXHIBIT C 
 STOCK PURCHASE AGREEMENT 
 THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is executed and
effective as of                     , 2009 by and between Cell Genesys, Inc., a Delaware corporation (the “Company”), and
BioMed Realty, L.P., a Maryland limited partnership (“BioMed”). 
 RECITALS 
 WHEREAS, pursuant to the terms of that certain Agreement for Termination of Lease and Voluntary Surrender of Premises between the Company and BMR-Bridgeview Technology
Park II LLC, a Delaware limited liability company (the “Landlord”), dated as of March 6, 2009 (the “Termination Agreement”), the Company and the Landlord terminated the Lease Agreement dated as of
January 7, 2002 between the Landlord (as successor in interest to F & S Hayward II, LLC, a Delaware limited liability company) and the Company, subject to the satisfaction of certain Termination Conditions, as defined in the Termination
Agreement; 
 WHEREAS, the Termination Condition contained in Section 8(d) of the Termination Agreement has been satisfied as of the date hereof; and

 WHEREAS, in accordance with Section 4 of the Termination Agreement, the Company and BioMed, the sole member of Landlord, enter into this Agreement
pursuant to which the Company shall issue to BioMed, and BioMed acquire from the Company, an aggregate of One Million (1,000,000) shares (the “Shares”) of the Company’s Common Stock, par value $0.001 per share (the
“Common Stock”), on the terms and subject to the conditions specified herein. 
 NOW, THEREFORE, in consideration of the premises and mutual
covenants contained herein, the parties hereto hereby agree as follows: 
 1. Issuance of Shares. 
 1.1 Issuance of Shares. On the date hereof and subject to the terms and conditions of this Agreement, in consideration of entering
into the Termination Agreement and for other good and valuable consideration the sufficiency of which is hereby recognized, the Company agrees to issue to BioMed, and BioMed agrees to acquire from the Company, the Shares. 
 1.2 Delivery of Shares. No later than two (2) business days following the date hereof, the Company shall deliver to BioMed or
cause to be delivered to BioMed, a share certificate registered in BioMed’s name representing the Shares that BioMed is to receive from the Company. 
 2. Representations and Warranties of the Company. The Company hereby represents and warrants to BioMed as of the date hereof, and with respect to Sections 2.7, 2.8, 2.9 and 2.10 for so long as BioMed holds the
Shares, as follows: 
 2.1 Organization; Good Standing. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as presently conducted and as proposed to be conducted, and is qualified to do business as a foreign
corporation in good standing in all other jurisdictions in which the conduct of its business requires such qualification. 
  

 C-1 

 2.2 Authorization. All corporate action on the part of the Company, its respective
officers, directors and shareholders necessary for the authorization, execution and delivery of this Agreement, the performance of all obligations of the Company hereunder, and the authorization, issuance and delivery of the Shares has been taken,
and this Agreement constitutes a valid and legally binding obligation of the Company, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general
application affecting enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. The Shares being purchased by BioMed
hereunder, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable, and not subject to preemptive or other similar rights of
the Company’s stockholders or others. 
 2.3 Percentage of Outstanding Stock. The Shares represent less than five
percent (5.0%) of the voting interest and less than five percent (5.0%) of the value of the outstanding stock of the Company. 
 2.4 Securities Laws. Subject to the accuracy of the representations and warranties of BioMed set forth in Section 3 below, the offering, issuance and sale of the Shares to BioMed is exempt from the
registration requirements of Section 5 of the Securities Act of 1933, as amended (“Securities Act”) by virtue of Rule 506 of Regulation D promulgated by the Securities Act, and no consent, approval, qualification, registration
or filing under any federal or state securities law is required in connection therewith, except for the filing of a Form D, which shall be filed with the Securities and Exchange Commission after the Shares are issued and which the Company agrees to
file in a timely manner whenever required. Rule 506 of Regulation D is available to the offering, issuance, sale and delivery of the Shares to BioMed because, among other things, (1) there has been no general solicitation or general
advertisement in connection with such offering, issuance and sale to BioMed, and (2) there are no other offerings of securities of the Company which could be integrated with the offering, issuance and sale of the Shares contemplated by this
Agreement. 
 2.5 Restrictions. The Shares will be free of restrictions on transfer other than restrictions on transfer
set forth in this Agreement. 
 2.6 No Violation. Neither the execution, delivery and performance of this Agreement by
the Company nor the issuance, sale and delivery of the Shares contemplated hereby will violate, conflict with or result in any breach of any of the terms, conditions or provisions of, constitute a default under, or require any consent not obtained
as of the date hereof under, (1) the certificate of incorporation or by-laws of the Company, (2) any agreement, contract, arrangement or understanding to which the Company is a party (including, but not limited to, any shareholders’
or similar agreements), or (3) any statute or any rule, regulation, order, judgment or decree of any court or other governmental body applicable to the Company. 
 2.7 Health Care / Lodging Facilities. The Company does not operate or manage any health care facilities (including a congregate
care facility or assisted living facility) or lodging facilities or provide any person, under a franchise, license or otherwise, rights to any brand name under which any lodging facility or health care facility is operated. 
  

 C-2 

 2.8 Annual Reports. The Company shall furnish to BioMed, as soon as practicable
and in any event within 90 days after the end of each fiscal year of the Company, audited, consolidated annual financial statements certified by an independent certified public accountant and prepared in accordance with U.S. GAAP; provided, however,
that so long as the Company remains subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company may satisfy this requirement by the timely filing of such financial
statements with the Securities and Exchange Commission. 
 2.9 Quarterly Information. The Company shall furnish to
BioMed, as soon as practicable and in any event within 15 days after the end of each calendar quarter, (i) a capitalization table setting forth all of the capital stock issued and outstanding or issuable by the Company, including the value of
such capital stock, the voting power of such capital stock and the rights of such capital stock to appoint directors of the Company; provided, however, that so long as the Company remains subject to the reporting requirements of the Exchange Act,
the Company may satisfy this requirement by timely filing its quarterly reports on Form 10-Q and annual report on Form 10-K with the Securities and Exchange Commission; and (ii) such other information as is reasonably requested by BioMed to be
necessary or helpful to monitor BioMed’s compliance with the requirements relating to the status of BioMed or its affiliates as a real estate investment trust for federal income tax purposes. 
 2.10 Notification. In the event that the Company becomes aware of any event which has resulted or which may result in the Shares
held by BioMed constituting greater than five percent (5.0%) of the voting interest and/or greater than five percent (5.0%) of the value of the outstanding stock of the Company, the Company shall immediately notify BioMed, and in no event
later than five (5) days after the occurrence of such event. 
 3. Representations and Warranties of BioMed to the Company.
BioMed hereby represents and warrants to the Company as of the date hereof that: 
 3.1 Authorization. All corporate
action on the part of BioMed, its respective officers, directors, members and shareholders necessary for the authorization, execution and delivery of this Agreement, and the performance of all obligations of BioMed hereunder, has been taken, and
such Agreement constitutes a valid and legally binding obligation of BioMed, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating to the availability or specific performance, injunctive relief, or other equitable remedies. 
 3.2 No Violation. Neither the execution, delivery and performance of this Agreement by BioMed nor the acquisition by BioMed of the
Shares will violate, conflict with or result in any breach of any of the terms, conditions or provisions of, constitute a default under, or require any consent not obtained as of the date hereof under, (1) the certificate of incorporation or
by-laws of BioMed, (2) any agreement, contract, arrangement or understanding to which BioMed is a party (including, but not limited to, any shareholders’ or similar agreements), or (3) any statute or any rule, regulation, order,
judgment or decree of any court or other governmental body applicable to BioMed. 
  

 C-3 

 3.3 Purchase Entirely for Own Account. This Agreement is made with BioMed in
reliance upon BioMed’s representation to the Company, which by BioMed’s execution of this Agreement BioMed hereby confirms, that the Shares to be received by BioMed will be acquired for investment for BioMed’s own account, not as a
nominee or agent, and not with a view to the resale or distribution of any part thereof, and that BioMed has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, BioMed
further represents that BioMed does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to such person or to any third person, with respect to any of the Shares. 
 3.4 Investment Experience. BioMed is an “accredited investor” within the meaning of Rule 501 of Regulation D under the
Securities Act. BioMed acknowledges that it can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Shares.
BioMed also represents it has not been organized solely for the purpose of acquiring the Shares. 
 3.5 Restricted
Securities. BioMed understands that the Shares it is purchasing are characterized as “restricted securities” under the Securities Act inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances. In addition, BioMed represents that it is familiar with Rule 144 under
the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act. 
 3.6 Legends. It is understood that the certificate(s) evidencing the Shares shall bear the following legend: 
 THE SHARES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION UNLESS THE COMPANY RECEIVES AN OPINION OF
COUNSEL REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT OR UNLESS SOLD PURSUANT TO RULE 144 OF THE ACT. 
 4. Notification. BioMed agrees to promptly notify the Company after it disposes of all of the Shares issued to BioMed hereunder. 
 5. Lock-Up. BioMed will not, during the period ending 90 days after the date of issuance of the Shares, (i) offer, pledge, announce the
intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any of the
Shares, or any securities convertible into or exercisable or exchangeable for the Shares or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic 

  

 C-4 

 
consequences of ownership of the Shares, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of the
Shares or such other securities, in cash or otherwise. In furtherance of the foregoing, the Company and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make
any transfer of securities if such transfer would constitute a violation or breach of this Agreement. 
 6. Piggyback Registration. If
at any time prior to 90 days after the date of issuance of the Shares (but without any obligation to do so) the Company proposes to register any additional shares of its Common Stock or other securities under the Securities Act in connection with
the public offering of such securities (other than (a) a registration statement relating to the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan, (b) a registration statement on Form
S-4, or (c) a registration statement on a form not available for registering the Shares), the Company shall, at such time, promptly give BioMed written notice of such registration. Upon the written request of BioMed given within five
(5) days after mailing of such notice by the Company, the Company shall use its commercially reasonable efforts to cause to be registered under the Securities Act all of the Shares that BioMed has requested to be registered (subject to any
limitations or cutbacks that may be required by an underwriter if such public offering is an underwritten public offering); provided, however, that the Company shall have the right to postpone or withdraw any registration statement pursuant to this
Section 6 without obligation to BioMed. 
 7. Miscellaneous. 
 7.1 Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any
rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 7.2 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California.

 7.3 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. 
 7.4 Titles and Subtitles. The titles and subtitles
used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 7.5 Notices. All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall in any event be deemed to be given upon receipt or, if earlier, (a) five
(5) days after deposit with the U.S. Postal Service or other applicable postal service, if delivered by first class mail, postage prepaid, (b) upon 

  

 C-5 

 
delivery, if delivered by hand, (c) one (1) business day after the business day of deposit with Federal Express or similar overnight courier,
freight prepaid or (d) one (1) business day after the business day of facsimile transmission (with confirmation), if delivered by facsimile transmission with copy by first class mail, postage prepaid, and shall be addressed (i) if to
BioMed, at 17190 Bernardo Center Drive, San Diego, CA 92128, Attn: General Counsel/Corporate Legal; and (ii) if to the Company, at the address or facsimile number of the Company’s principal corporate offices, or at such other address as a
party may designate by ten days’ advance written notice to the other party pursuant to the provisions above. 
 7.6
Costs and Expenses. Each party shall pay its respective expenses in connection with the preparation, execution and delivery of this Agreement and the transactions contemplated hereby, including the fees and out-of-pocket expenses of legal
counsel. 
 7.7 Amendment and Waivers. Any term of this Agreement may be amended and the severance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the parties hereto. 
 7.8 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision
shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 
 7.9 Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no
party shall be liable or bound to any other party in any manner by any warranties, representations, or covenants except as specifically set forth herein or therein. 
 [Remainder of page intentionally left blank.] 
  

 C-6 

 The parties have executed this Stock Purchase Agreement as of the date first above written. 

 

			
	CELL GENESYS, INC.
		
	By:	 	 
	Name:	 	 
	Title:	 	Chief Financial Officer

  

			
	BIOMED REALTY, L.P.
		
	By:	 	 
	Name:	 	 
	Title:	 	 

 [SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT] 
  

 C-7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]